Skip to main content
NCBI home page
Journal of Experimental Pathology (Oxford, England) logoLink to Journal of Experimental Pathology (Oxford, England)
. 1990 Feb;71(1):69–82.

Cyclosporin A modulation of the acute inflammatory response: an explanation for the effect of CsA on host defences in infection.

D J Ormrod 1, S Cawley 1, T E Miller 1
PMCID: PMC1998673  PMID: 2106909

Abstract

Previous studies have shown that the administration of cyclosporin A (CsA) to animals with experimentally induced pyelonephritis resulted in considerable exacerbation of infection. T-lymphocytes are not involved in the host response to pyelonephritis but neutrophils are known to be a key component in the pathogenesis of this infection, so the effect of CsA on this inflammatory component was investigated. CsA administration did not affect the metabolic activity of neutrophils in vitro nor their ability to phagocytose and kill microorganisms. However, the ability of neutrophils to mobilize to a sterile inflammatory focus in vivo was significantly impaired. Further experiments, using models of pyelonephritis and subcutaneous infection, demonstrated that the CsA-induced suppression of neutrophil mobilization was directly related to the observed increase in bacterial numbers and exacerbation of tissue damage. Additionally, the actual effect of CsA on host defences and the outcome of infection was found to be dependent on the level of the initial infectious challenge. The results of this study provide an explanation for the current pattern of infectious disease in patients treated with CsA, in whom infection with extracellular pathogens is still common. It is also clear that the effect of CsA on inflammatory mechanisms may explain the efficacy of the agent in inflammatory diseases such as rheumatoid arthritis. This suggests a wider therapeutic role for CsA than is currently recognized.

Full text

PDF
69

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amor B., Dougados M. Cyclosporine: therapeutic effects in rheumatic diseases. Transplant Proc. 1988 Jun;20(3 Suppl 4):218–223. [PubMed] [Google Scholar]
  2. Cyclosporine. Heart and lung transplantation. Transplant Proc. 1983 Dec;15(4 Suppl 1-2):2546–2581. [PubMed] [Google Scholar]
  3. Kharazmi A., Svenson M., Nielsen H., Birgens H. S. Effect of cyclosporin A on human neutrophil and monocyte function. Scand J Immunol. 1985 Jun;21(6):585–591. doi: 10.1111/j.1365-3083.1985.tb01848.x. [DOI] [PubMed] [Google Scholar]
  4. Löliger C., Lehmann-Grube F. Mechanism of recovery from acute virus infection. II. Effect of treatment of mice with cyclosporin A on their ability to eliminate the lymphocytic choriomeningitis virus. Med Microbiol Immunol. 1985;174(4):187–196. doi: 10.1007/BF02123695. [DOI] [PubMed] [Google Scholar]
  5. Miller T. E., Findon G. Exacerbation of experimental pyelonephritis by cyclosporin A. J Med Microbiol. 1988 Aug;26(4):245–250. doi: 10.1099/00222615-26-4-245. [DOI] [PubMed] [Google Scholar]
  6. Miller T. E., Findon G. Modulation of host defenses against pyogenic microorganisms by cyclosporine. Transplantation. 1986 Nov;42(5):463–466. doi: 10.1097/00007890-198611000-00004. [DOI] [PubMed] [Google Scholar]
  7. Miller T. Pyelonephritis: the role of cell-mediated immunity defined in a congenitally athymic rat. Kidney Int. 1984 Dec;26(6):816–822. doi: 10.1038/ki.1984.223. [DOI] [PubMed] [Google Scholar]
  8. Moffat F. L., Falk R. E., Teodorczyk-Injeyan J., Clark A. G., Gilas T., Falk M., Dalfen R., Rotstein L. E., McDonell M., Makowka L. Reversal of cyclosporine-induced mortality with a synthetic polymeric immunostimulant in a murine model of fecal peritonitis. Transplantation. 1985 Apr;39(4):369–374. doi: 10.1097/00007890-198504000-00006. [DOI] [PubMed] [Google Scholar]
  9. Murray B. M., Paller M. S., Ferris T. F. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int. 1985 Nov;28(5):767–774. doi: 10.1038/ki.1985.196. [DOI] [PubMed] [Google Scholar]
  10. Perfect J. R., Durack D. T. Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun. 1985 Oct;50(1):22–26. doi: 10.1128/iai.50.1.22-26.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pigatto P. D., Mozzanica N., Polenghi M. M., Altomare G. F., Finzi A. F. Cyclosporine A inhibits polymorphonuclear leukocyte chemotaxis in vivo. Transplant Proc. 1988 Jun;20(3 Suppl 4):91–94. [PubMed] [Google Scholar]
  12. Ponticelli C., Minetti L., Di Palo F. Q., Vegeto A., Belli L., Corbetta G., Tarantino A., Civati G. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation. 1988 May;45(5):908–913. doi: 10.1097/00007890-198805000-00013. [DOI] [PubMed] [Google Scholar]
  13. Schaffner A., Douglas H., Davis C. E. Models of T cell deficiency in listeriosis: the effects of cortisone and cyclosporin A on normal and nude BALB/c mice. J Immunol. 1983 Jul;131(1):450–453. [PubMed] [Google Scholar]
  14. Schopf R. E., Mattar J., Meyenburg W., Scheiner O., Hammann K. P., Lemmel E. M. Measurement of the respiratory burst in human monocytes and polymorphonuclear leukocytes by nitro blue tetrazolium reduction and chemiluminescence. J Immunol Methods. 1984 Feb 24;67(1):109–117. doi: 10.1016/0022-1759(84)90090-5. [DOI] [PubMed] [Google Scholar]
  15. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986 Oct;55(4):455–462. [PubMed] [Google Scholar]

Articles from Journal of experimental pathology (Oxford, England) are provided here courtesy of Wiley

RESOURCES